Advances in Glaucoma Therapy: Brimonidine Tartrate

References

• Makabe R. Ophthalmological studies with dichlorophenyl-aminoimidazoline. Dtsch Med Wochenschr. 1966; 91: 1686–1688
   PubMedGoogle Scholar
• Hoffman BB, Lefkowitz RJ. Catecholamines, sympathomimetic drugs, and adrenergic receptor antagnoists. Goodman and Gilman 's The Pharmacological Basis of Therapeutics, ed 9, JG Hardman, AG Gilman, LE Limbird. McGraw-Hill, New York, NY 1996; 199–248
   Google Scholar
• Krieglstein GK, Gramer E. The response of ophthalmic arterial pressure to topically applied clinidine. Graefes Arch Clin Exp Ophthalmol. 1978; 207: 1–5
   Google Scholar
• Hodapp E, Kolker AE, Kass MA, et al. The effect of topical clonidine on intraocular pressure. Arch Ophthalmol. 1981; 99: 1208–1211
   PubMed Web of Science ®Google Scholar
• Novack GD, Robin AL, Derick RJ. New medical treatments for glaucoma. Int Ophthalmol Clin. 1993; 33: 183–202
   PubMedGoogle Scholar
• Rouot B, Leclerc G, Bieth N. et al. Pharmacological study of para-aminoclonidine. an alpha sympathomimetic. C R Acad Scilll. 1978; 286: 909–912
   PubMedGoogle Scholar
• Chandler ML, De Santis L. Studies of p-aminoclonidine as a potential antiglaucoma agent. Invest Ophthalmol Vis Sci. 1985; 26(suppl)227
   Google Scholar
• Toris CB, Tafoya ME., Camras CB, et al. Effects of apraclonidine on aqueous humor dynamics in human eyes. Ophthalmology 1995; 102: 456–461
   PubMed Web of Science ®Google Scholar
• Brown RH, et al. ALO 2145 reduces the IOP elevation after anterior segment laser surgery. Ophthamology 1988; 95: 378–384
   PubMed Web of Science ®Google Scholar
• Holmwood PC, Chase RD, Kropin T, et al. Apraclonidine and argon laser trabeculoplasty. Am J Ophthalmol. 1992; 114: 19–22
   PubMed Web of Science ®Google Scholar
• Robin AL, Pollack IP., House B., et al. Effect of ALO-2145 on intraocular pressure following argon laser trabeculoplasty. Arch Ophthalmol. 1987; 105: 646–650
   PubMedGoogle Scholar
• Robin AL, Pollack IP, DeFaller JM. Effects of topical ALO 2145 (p-aminoclonidine hydrochloride) on intraocular pressure rise following argon laser iridotomy. Arch Ophthalmol. 1987; 105: 1208–1211
   PubMedGoogle Scholar
• Silverstone D, Brint E.S., Olander K, et al. Prophylactic use of apraclonidine for intraocular pressure increase after Nd. YAG capsulotomies. Am J Ophthalmol. 1992; 113: 401–405
   PubMed Web of Science ®Google Scholar
• Robin AL, Ritch R, Shin DH, et al. Short-term efficacy of apraclonidine hydrochloride added to maximum-tolerated medical therapy for glaucoma. Am J Ophthalmol. 1995; 120: 423–432
   PubMed Web of Science ®Google Scholar
• Butler P., Mannschreck M, Lin S, et al. Clinical experience with the long-term use of 1% apraclonidine: Incidence of allergic reactions. Arch Ophthalmol. 1995; 113: 293–296
   PubMed Web of Science ®Google Scholar
• Nagasubramanian S, Hitchings RA, Demaill P, et al. Comparison of apraclonidine and timolol in chronic open-angle glaucoma. Ophthalmology 1993; 100: 1318–1323
   PubMed Web of Science ®Google Scholar
• Stewart WC, Ritch R, Shin DH., et al. The efficacy of apraclonidine as an adjunct to timolol therapy. Arch Ophthalmol. 1995; 113: 287–292
   PubMedGoogle Scholar
• Araujo SV, Bond JB, Wilson RP, et al. Long term effect of apraclonidine. Br J Ophthalmol. 1995; 79: 1098–1101
   PubMed Web of Science ®Google Scholar
• Burke Padillo J.E., Shan T., et al. AGN 190342 (UK-14304–18) stimulates an imidazoline receptor to lower intraocular pressure (IOP) in conscious monkeys. Invest Ophthalmol Vis Sci. 1991; 32(suppl)867
   Google Scholar
• Tons CB., Gleason ML, Camras CB, et al. Effects of brimonidine on aqueous humor dynamics in human eyes. Arch Ophthalmol. 1995; 113: 1514–1517
   PubMedGoogle Scholar
• Burke JA, Potter DE. Ocular effects of a relatively selective a2 agonist (UK-14304–18) in cats, rabbits, and monkeys. CurrEyeRes. 1986; 5: 665–676
   Google Scholar
• Burke Crosson J., De Potter C. Can UK-14304–18 lower IOP in rabbits by a peripheral mechanism?. Curr Eye Res. 1989; 8: 547–552
   PubMed Web of Science ®Google Scholar
• Angelov O, Wiese A, Tang-Liu D., et al. Preclinical safety profile of brimonidine. Eur J Ophthalmol. 1996; 6: 21–25
   PubMedGoogle Scholar
• Gabelt BT, Robinson JC, Hubbard WC, et al. Apraclonidine and brimonidine effects on anterior ocular and cardiovascular physiology on normal and sympathectomized monkeys. Exp Eye Res. 1994; 59: 633–644
   PubMed Web of Science ®Google Scholar
• Burke J, Kharlamb A, Shan T, et al. Adrenergic and imidazoline receptor-mediated responses to UK-14302–18 (brimonidine) in rabbits and monkeys: A species difference. The Imidazoline Receptor: Pharmacology, Functions, Ligands, and Relevance to Biology and Medicine, D Reis, P Bousquet, A Parini. New York Academy of Sciences, New York, NY 1995; 78–95
   Google Scholar
• Kharlamb A, Shan T, Runde E, et al. The cynomolgus monkey has a CNS imidazoline receptor which mediates IOP and cardiovascular responses to UK-14304 (AGN 190342). Invest Ophthalmol Vis Sci. 1992; 33(suppl)1115
   Google Scholar
• Burke J, Manlapaz C, Kharlamb A, et al. Therapeutic use of α2-adrenoceptor agonists in glaucoma. Alpha₂-Adrenergic Receptors: Structure, Function and Therapeutic Implications, S Lanier, L Limbird. Harwood Academic Pub, ReadingUK 1996; 179–187
   Google Scholar
• Schuman JS. Clinical experience with brimonidine 0.2% and timolol 0.5% in glaucoma and ocular hypertension. Surv Ophthalmol. 1996; 41(suppl 1)S27–S37
   PubMed Web of Science ®Google Scholar
• Serle J BM. brimonidine study group III. A comparison of the safety and efficacy of twice daily brimonidine 0.2% versus betaxolol 0.25% in subjects with elevated intracoular pressure. Surv Ophthalmol. 1996; 41(suppl 1)S39–S47
   PubMed Web of Science ®Google Scholar
• Gluchowski C, Jeon YT, Wetzel JM, et al. Use of recombinant human alpha adrenergic receptors for the pharmacological evaluation of alpha adrenergic ocular hypotensive agents. Invest Ophthalmol Vis Sci. 1994; 35(suppl)S1399
   Google Scholar
• Langer SZ. Presynaptic receptors and the regulation of transmitter release in the peripheral and central nervous system. Sixth Gaddum Memorial Lecture. Br J Ophthalmol. 1977; 60: 481–497
   Google Scholar
• Kobilka BK, Kobilka TS, Daniel K, et al. Chimeric alpha2-, beta2-adrenergic receptors: Delineation of domains involved in effector coupling and ligand binding specificity. Science 1989; 240: 1310–1316
   Web of Science ®Google Scholar
• Barnebey HS, Robin AL, Zimmerman TJ, et al. The efficacy of brimonidine in decreasing elevation in intraocular pressure after laser trabeculoplasty. Ophthalmology 1993; 100: 1083–1088
   PubMed Web of Science ®Google Scholar
• Spada CS, Nieves AL, Burke JA, et al. Comparative effects of brimonidine, p-aminoclonidine and clonidine on arteriolar caliber in human retinal tissue. Invest Ophthalmol Vis Sci. 1995; 36(suppl)S1041
   Google Scholar
• Joyner WL, Gilmore JP. Tissues grafted into the cheek pouch of the hamster. Physical Techniques in Biology and Medicine, CH Baker, WL Nastuk. Academic, New York, NY 1986; 3–17
   Google Scholar
• Joyner WL, Tang T, Macek BA, et al. Human ocular microcirculation: Intravital microscopy of retinal and choroid circulations grafted into the cheek pouch of the hamster. Biology of the Ocular Microcirculation, RN Weinreb, WL Joyner, LA Wheeler. Elsevier, AmsterdamThe Netherlands 1992; 61–70
   Google Scholar
• Derick RJ, Robin AL, Walters TR, et al. Brimonidine Tartrate: a one-month dose response study. Ophthalmology 1997; 104: 131–136
   PubMed Web of Science ®Google Scholar
• Rosenthal AL, Walters T, Berg E, et al. A comparison of the safety and efficacy of brimonidine 0.2%, bid versis tid, in subjects with elevated intraocular pressure. Invest Ophthalmol Vis Sci. 1996; 37(suppl)1102
   Google Scholar
• David R, Spaeth GL, Clevenger CE, et al. Brimonidine in the prevention of intraocular pressure elevation following argon laser trabeculoplasty. Arch Ophthalmol. 1993; 111: 1387–1390
   PubMedGoogle Scholar
• Brimonidine-ALT Study Group. Effect of brimonidine 0.5% on intaocular pressure spikes following 360° argon laser trabeculoplasty. Ophth Surg Lasers 1995; 26: 404–409
   PubMedGoogle Scholar
• Nordlund JR, Pasquale LR, Robin AL, et al. The cardiovascular, pulmonary, and ocular hypotensive effects of 0.2% brimonidine. Arch Ophthalmol. 1995; 113: 77–83
   PubMedGoogle Scholar
• Ashton H, Rawlins MD. Central nervous system depressant actions of clonidine and UK-14,304: Partial dissociation of EEG and behavioural effects. Br J Clin Pharmacol. 1978; 5: 135–140
   PubMed Web of Science ®Google Scholar
• Acheampong AA, Shackleton M, Tang-Liu D DS. Comparative ocular pharmacokinetics of brimonidine after a single dose application to the eyes of albino and pigmented rabbits. Drug Metab Dispos. 1995; 27: 708–712
   Google Scholar
• Munk SA, Wiese A, Thompson CD, et al. Oxidation potential and allergic response of a2 agonists. Invest Ophthalmol Vis Set 1996; 37(suppl)S832
   Google Scholar
• Dreyer EB, Zurakowski D, Schumer RA, et al. Elevated glutamate levels in the vitreous body of humans and monkeys with glaucoma. Arch Ophthalmol. 1996; 114: 299–305
   PubMed Web of Science ®Google Scholar
• Vorwerk CK, Lipton SA, Zurakowski D, et al. Chronic low-dose glutamate is toxic to retinal ganglion cells: Toxicity blocked by memantine. Invest Ophthalmol Vis Sci. 1996; 37: 1618–1624
   PubMed Web of Science ®Google Scholar
• Schwartz M, Belkin M, Yoles E, et al. Potential treatment modalities for glaucomatous neuropathy: Neuroprotection and neuroregeneration. J Glaucoma. 1996; 5: 427–432
   PubMed Web of Science ®Google Scholar
• Maier C, Steinberg GK, Sun GH, et al. Neuroprotection by the alpha-2 adrenoceptor agonist dexmedetomidine in a focal model of cerebral ischemia. Anesthesiology 1993; 79: 306–312
   PubMed Web of Science ®Google Scholar
• Yoles E, Muler S, Schwartz M, et al. Injury-induced secondary degeneration of rat optic nerve can be attenuated by alpha2-adrenoceptor agonists AGN 191103 and brimonidine. Invest Ophthalmol Vis Sci. 1996; 37(suppl)S114
   PubMedGoogle Scholar